Taking into consideration that YKL-39 was demonstrated by us as a pro-angiogenic factor and chemoattractant for monocytes, we suggest that YKL-39 is a promising target for cancer therapy and that targeting of YKL-39 can be considered in combination with NAC in breast cancer patients in order to reduce the risk of metastasis formation. Here, CHI3L2 is linked to breast carcinoma.